Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group
According to available evidence and data, belzutifan has generally been well tolerated, though anemia is a frequent on-target side effect and, along with hypoxia, necessitates monitoring throughout treatment. As reported, ongoing phase III clinical trials are set to yield potentially practice-changing results, investigating innovative combinatorial strategies including belzutifan. Ongoing advancement of predictive biomarkers and understanding of resistance mechanisms could improve patient selection and identify new drug targets, thereby increasing the clinical efficacy of belzutifan.
Authors
- Francesco Ciccimarra (ORCID: https://orcid.org/0009-0009-7321-0950)
- V. Mollica
- Maria Teresa Bourlon (ORCID: https://orcid.org/0000-0002-3116-912X)
- Gerardo Cazzato (ORCID: https://orcid.org/0000-0003-0325-4316)
- Andrey Coatrini Soares (ORCID: https://orcid.org/0000-0003-4601-3555)
- Hana Študentová (ORCID: https://orcid.org/0000-0003-2105-9258)
- Concetta Calabrò (ORCID: https://orcid.org/0009-0008-6915-0820)
- B. Melichar
- Francesco Massari (ORCID: https://orcid.org/0000-0001-6476-6871)
- Fernando Sabino Marques Monteiro (ORCID: https://orcid.org/0000-0002-6621-8251)
- Raffaella Massafra (ORCID: https://orcid.org/0000-0001-8588-261X)
- Patrizia Nardulli (ORCID: https://orcid.org/0000-0002-2240-5186)
- Timothy Schieber
- Mario Della Mura (ORCID: https://orcid.org/0009-0009-5116-2484)
- Jakub Kucharz
- Matteo Santoni
- Javier Molina-Cerrillo
- Alessandro Rizzo
- Tarek Taha
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Hospital Israelita Albert Einstein (BR)
- Arnold Ventures (US)
- Eastern Cooperative Oncology Group (US)
- The University of Kansas Cancer Center (US)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Azienda USL di Bologna (IT)
- National Institute of Oncology (HU)
- Istituto Tumori Bari (IT)
- Hospital Sírio-Libanês (BR)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Hospital Universitario Ramón y Cajal (ES)
- Ospedale di Macerata
- University of Bari Aldo Moro (IT)
- Palacký University Olomouc (CZ)
- University of Bologna (IT)
Publication Details
- Journal
- Expert Opinion on Pharmacotherapy
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/14656566.2026.2627934
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00